# US 2012/0232303 A1 · Crystalline Solid and Amorphous Forms of (-)-Halofenate and Methods Related Thereto

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0232303 A1
- Document ID: US20120232303A1
- Status: Published application
- Kind: A1
- Application number: 13/470,142
- Filed: 2012-05-11
- Published: 2012-09-13
- Earliest claimed: 2005-04-20
- Assignees: DiaTex, Inc.; Metabolex, Inc.
- Inventors: Edward D. Daugs; Eric J. Hagen; Jason A. Hanko; David H. Louks
- Web page: https://patentgrep.com/patent/US20120232303A1

## CPC

- C07C 233/18: having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 31/216: of acids having aromatic rings, e.g. benactizyne, clofibrate
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- C07C 235/78: the carbon skeleton containing rings
- C07B 2200/07: Optical isomers
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

The present invention provides crystalline solid and amorphous forms of (−)-halofenate. The crystalline solid forms may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of conditions associated with blood lipid deposition in a mammal, particularly those diseases related to Type 2 diabetes and hyperlipidemia. The invention also relates to a method for preventing or treating Type 2 diabetes and hyperlipidemia in a mammal comprising the step of administering a therapeutically effective amount of crystalline solid and amorphous forms of (−)-halofenate.

## Claims

### Claim 1

The compound (−)-halofenate in a crystalline solid form A characterized by at least one of:
(i) an infra red spectrum substantially in accordance with FIG. 3;
(ii) a Raman spectrum substantially in accordance with FIG. 5;
(iii) an X-ray powder diffraction pattern substantially in accordance with FIG. 1; and
(iv) a DSC scan substantially in accordance with FIG. 7.

### Claim 2

The compound (−)-halofenate in a crystalline solid form A characterized by an infra red spectrum substantially in accordance with FIG. 3.

### Claim 3

The compound (−)-halofenate in a crystalline solid form A characterized by a Raman spectrum substantially in accordance with FIG. 5.

### Claim 4

The compound (−)-halofenate in a crystalline solid form A characterized by at least one of
(i) an infra red spectrum comprising absorption peaks at about 3479, 3322, 3082, 2886, 2842, 1918, 1850, 1753, 1709, 1651, 1596, 1548, 1494, 1461, 1430, 1371, 1340, 1272, 1231, 1127, 1070, 1017, 926, 903 and 884 cm−1;
(ii) a Raman spectrum comprising absorption peaks at about 3087, 3071, 2959, 2933, 2857, 1747, 1663, 1647, 1622, 1598, 1451, 1433, 1333, 1290, 1274, 1231, 1208, 1177, 1095, 1015, 1001, 964, 948, 926, 905, 882, 872, 833, 767, 757, 723 and 631 cm−1;
(iii) an X-ray powder diffraction pattern comprising peaks at about 10.8°2θ, about 22.0°2θ and about 29.3°2θ; and
(iv) a DSC maximum endotherm at about 80° C.

### Claim 5

The compound (−)-halofenate in a crystalline solid form A characterized by an X-ray powder diffraction pattern comprising peaks at about 10.8°2θ and about 22.0°2θ, and about 29.3°2θ.

### Claim 6

The compound (−)-halofenate in a crystalline solid form A characterized by a DSC maximum endotherm at about 80° C.

### Claim 7

The compound (−)-halofenate in a substantially pure crystalline solid form A characterized by at least one of:
(i) an infra red spectrum substantially in accordance with FIG. 3;
(ii) a Raman spectrum substantially in accordance with FIG. 5;
(iii) an X-ray powder diffraction pattern substantially in accordance with FIG. 1; and
(iv) a DSC scan substantially in accordance with FIG. 7.

### Claim 8

The compound (−)-halofenate in a substantially pure crystalline solid form A characterized by an infra red spectrum substantially in accordance with FIG. 3.

### Claim 9

The compound (−)-halofenate in a substantially pure crystalline solid form A characterized by a Raman spectrum substantially in accordance with FIG. 5.

### Claim 10

The compound (−)-halofenate in a substantially pure crystalline solid form A characterized by at least one of
(i) an infra red spectrum comprising absorption peaks at about 3479, 3322, 3082, 2886, 2842, 1918, 1850, 1753, 1709, 1651, 1596, 1548, 1494, 1461, 1430, 1371, 1340, 1272, 1231, 1127, 1070, 1017, 926, 903 and 884 cm−1;
(ii) a Raman spectrum comprising absorption peaks at about 3087, 3071, 2959, 2933, 2857, 1747, 1663, 1647, 1622, 1598, 1451, 1433, 1333, 1290, 1274, 1231, 1208, 1177, 1095, 1015, 1001, 964, 948, 926, 905, 882, 872, 833, 767, 757, 723 and 631 cm−1;
(iii) an X-ray powder diffraction pattern comprising peaks at about 10.8°2θ and about 22.0°2θ, and about 29.3°2θ and
(iv) a DSC maximum endotherm at about 80° C.

### Claim 11

The compound (−)-halofenate in a substantially pure crystalline solid form A characterized by an X-ray powder diffraction pattern comprising peaks at about 10.8 °2θ about 22.0°2θ, and about 29.3°2θ.

### Claim 12

The compound (−)-halofenate in a substantially pure crystalline solid form A characterized by a DSC maximum endotherm at about 80° C.

### Claim 13

The compound (−)-halofenate in a crystalline solid form B characterized by at least one of:
(i) an X-ray powder diffraction pattern substantially in accordance with FIG. 13; and
(ii) a DSC scan substantially in accordance with FIG. 15.

### Claim 14

The compound (−)-halofenate in a crystalline solid form B characterized by at least one of:
(i) an X-ray powder diffraction pattern comprising peaks at about 6.2°2θ and about 12.4°2θ; and
(ii) a DSC endotherm maximum of about 71° C.

### Claim 15

The compound (−)-halofenate in a crystalline solid form B characterized by an X-ray powder diffraction pattern comprising peaks at about 6.2°2θ and about 12.4°2θ.

### Claim 16

The compound (−)-halofenate in a crystalline solid form B characterized by a DSC endotherm maximum of about 71° C.

### Claim 17

The compound (−)-halofenate in a substantially pure crystalline solid form B characterized by at least one of:
(i) an X-ray powder diffraction pattern substantially in accordance with FIG. 13; and
(ii) a DSC scan substantially in accordance with FIG. 15.

### Claim 18

The compound (−)-halofenate in a substantially pure crystalline solid form B characterized by at least one of:
(i) an X-ray powder diffraction pattern comprising peaks at about 6.2°2θ and about 12.4°2θ; and
(ii) a DSC endotherm maximum of about 71° C.

### Claim 19

The compound (−)-halofenate in a substantially pure crystalline solid form B characterized by an X-ray powder diffraction pattern comprising peaks at about 6.2 °2θ and about 12.4°2θ.

### Claim 20

The compound (−)-halofenate in a substantially pure crystalline solid form B characterized by a DSC endotherm maximum of about 71° C.

### Claim 21

The compound (−)-halofenate in a crystalline solid form C characterized by at least one of:
(i) an X-ray powder diffraction pattern substantially in accordance with FIG. 16; and
(ii) a DSC scan substantially in accordance with FIG. 17.

### Claim 22

The compound (−)-halofenate in a crystalline solid form C characterized by an X-ray powder diffraction pattern comprising peaks at about 9.9°2θ and about 13.3°2θ.

### Claim 23

The compound (−)-halofenate in a substantially pure crystalline solid form C characterized by at least one of:
(i) an X-ray powder diffraction pattern substantially in accordance with FIG. 16; and
(ii) a DSC scan substantially in accordance with FIG. 17.

### Claim 24

The compound (−)-halofenate in a substantially pure crystalline solid form C characterized by an X-ray powder diffraction pattern comprising peaks at about 9.9 °2θ and about 13.3°2θ.

### Claim 25

The compound (−)-halofenate in a crystalline solid form D characterized by at least one of:
(i) an infra red spectrum substantially in accordance with FIG. 20;
(ii) a Raman spectrum substantially in accordance with FIG. 22; and
(iii) an X-ray powder diffraction pattern substantially in accordance with FIG. 18.

### Claim 26

The compound (−)-halofenate in a crystalline solid form D characterized by an infra red spectrum substantially in accordance with FIG. 20.

### Claim 27

The compound (−)-halofenate in a crystalline solid form D characterized by a Raman spectrum substantially in accordance with FIG. 22.

### Claim 28

The compound (−)-halofenate in a crystalline solid form D characterized by at least one of:
(i) an infra red spectrum comprising absorption peaks at about 3469, 3297, 3086, 2968, 2930, 2870, 1747, 1740, 1703, 1647, 1597, 1554, 1492, 1460, 1429, 1369, 1345, 1295, 1232, 1209, 1193, 1124, 1069, 1015, 906, 880, 838, 819 cm−1;
(ii) a Raman spectrum comprising absorption peaks at about 3077, 3063, 2970, 2932, 1743, 1649, 1621, 1598, 1430, 1329, 1208, 1192, 1182, 1093, 1000, 936, 906, 881, 756, 723 and 632 cm−1; and
(iii) an X-ray powder diffraction pattern comprising peaks at about 9.6°2θ and about 17.4°2θ; and
(iv) a DSC endotherm maximum at about 74° C.

### Claim 29

The compound (−)-halofenate in a crystalline solid form D characterized by an X-ray powder diffraction pattern comprising peaks at about 9.6°2θ and about 17.4°2θ.

### Claim 30

The compound (−)-halofenate in a crystalline solid form D characterized by a DSC endotherm maximum at about 74° C.

### Claim 31

The compound (−)-halofenate in a substantially pure crystalline solid form D characterized by at least one of:
(i) an infra red spectrum substantially in accordance with FIG. 20;
(ii) a Raman spectrum substantially in accordance with FIG. 22; and
(iii) an X-ray powder diffraction pattern substantially in accordance with FIG. 18.

### Claim 32

The compound (−)-halofenate in a substantially pure crystalline solid form D characterized by an infra red spectrum substantially in accordance with FIG. 20.

### Claim 33

The compound (−)-halofenate in a substantially pure crystalline solid form D characterized by a Raman spectrum substantially in accordance with FIG. 22.

### Claim 34

The compound (−)-halofenate in a substantially pure crystalline solid form D characterized by at least one of:
(i) an infra red spectrum comprising absorption peaks at about 3469, 3297, 3086, 2968, 2930, 2870, 1747, 1740, 1703, 1647, 1597, 1554, 1492, 1460, 1429, 1369, 1345, 1295, 1232, 1209, 1193, 1124, 1069, 1015, 906, 880, 838, 819 cm−1;
(ii) a Raman spectrum comprising absorption peaks at about 3077, 3063, 2970, 2932, 1743, 1649, 1621, 1598, 1430, 1329, 1208, 1192, 1182, 1093, 1000, 936, 906, 881, 756, 723 and 632 cm−1; and
(iii) an X-ray powder diffraction pattern comprising peaks at about 9.6°2θ and about 17.4°2θ; and
(iv) a DSC endotherm maximum at about 74° C.

### Claim 35

The compound (−)-halofenate in a substantially pure crystalline solid form D characterized by an X-ray powder diffraction pattern comprising peaks at about 9.6 °2θ and about 17.4°2θ.

### Claim 36

The compound (−)-halofenate in a substantially pure crystalline solid form D characterized by a DSC endotherm maximum at about 74° C.

### Claim 37

The compound (−)-halofenate in a crystalline solid form E characterized by at least one of:
(i) a infra red spectrum substantially in accordance with FIG. 28;
(ii) a Raman spectrum substantially in accordance with FIG. 30; and
(iii) a X-ray powder diffraction pattern substantially in accordance with FIG.

### Claim 38

The compound (−)-halofenate in a crystalline solid form E characterized by a infra red spectrum substantially in accordance with FIG. 28.

### Claim 39

The compound (−)-halofenate in a crystalline solid form E characterized by a Raman spectrum substantially in accordance with FIG. 30.

### Claim 40

The compound (−)-halofenate in a crystalline solid form E characterized by at least one of:
(i) an infra red spectrum comprising absorption peaks at about 3475, 3301, 3092, 2969, 2933, 2871, 1750, 1706, 1660, 1597, 1563, 1493, 1460, 1429, 1370, 1338, 1232, 1178, 1126, 1070, 1015, 906, 886 and 820 cm−1;
(ii) a Raman spectrum comprising absorption peaks at about 3071, 2969, 2933, 1746, 1657, 1621, 1598, 1448, 1432, 1334, 1291, 1232, 1179, 1094, 1001, 907, 881, 767, 756, 722 and 632 cm−1; and
(iii) an X-ray powder diffraction pattern comprising peaks at about 11.8°2θ and about 13.0°2θ.

### Claim 41

The compound (−)-halofenate in a crystalline solid form E characterized by an X-ray powder diffraction pattern comprising peaks at about 11.8°2θ and about 13.0°2θ.

### Claim 42

The compound (−)-halofenate in a substantially pure crystalline solid form E characterized by at least one of:
(i) a infra red spectrum substantially in accordance with FIG. 28;
(ii) a Raman spectrum substantially in accordance with FIG. 30; and
(iii) a X-ray powder diffraction pattern substantially in accordance with FIG.

### Claim 43

The compound (−)-halofenate in a substantially pure crystalline solid form E characterized by a infra red spectrum substantially in accordance with FIG. 28.

### Claim 44

The compound (−)-halofenate in a substantially pure crystalline solid form E characterized by a Raman spectrum substantially in accordance with FIG. 30.

### Claim 45

The compound (−)-halofenate in a substantially pure crystalline solid form E characterized by at least one of:
(i) an infra red spectrum comprising absorption peaks at about 3475, 3301, 3092, 2969, 2933, 2871, 1750, 1706, 1660, 1597, 1563, 1493, 1460, 1429, 1370, 1338, 1232, 1178, 1126, 1070, 1015, 906, 886 and 820 cm−1;
(ii) a Raman spectrum comprising absorption peaks at about 3071, 2969, 2933, 1746, 1657, 1621, 1598, 1448, 1432, 1334, 1291, 1232, 1179, 1094, 1001, 907, 881, 767, 756, 722 and 632 cm−1; and
(iii) an X-ray powder diffraction pattern comprising peaks at about 11.8°2θ and about 13.0°2θ.

### Claim 46

The compound (−)-halofenate in a substantially pure crystalline solid form E characterized by an X-ray powder diffraction pattern comprising peaks at about 11.8 °2θ and about 13.0°2θ.

### Claim 47

The compound (−)-halofenate in an amorphous form.

### Claim 48

The compound (−)-halofenate in a substantially pure amorphous form characterized by an X-ray powder diffraction pattern comprising a broad peak substantially between about 15 and about 30°2θ.

### Claim 49

The compound (−)-halofenate in a substantially pure amorphous form characterized by an X-ray powder diffraction pattern substantially in accordance with FIG.

### Claim 50 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The compound according to any one of claims 1 to 12 having crystalline solid form A obtained by at least one of:
(i) heating (−)-halofenate in at least one solvent selected from the group consisting of heptane, 2-propanol, and combinations thereof; crystallizing at a temperature of from about 50° C. to −10° C. and drying until the crystals contain less than 0.05% solvent;
(ii) drying a crystal of solid form B of (−)-halofenate;
(iii) drying a crystal of solid form C of (−)-halofenate;
(iv) heating (−)-halofenate in at least one solvent selected from the group consisting of heptane, 2-propanol, and combinations thereof; crystallizing in the presence of a crystal of a solid form of (−)-halofenate at a temperature of from about 50° C. to −10° C. and drying until the crystals contain less than 0.05% solvent; and
(v) crystallizing (−)-halofenate from at least one solvent selected from the group consisting of acetonitrile, benzene, cyclohexanol, t-butyl methyl ether, methanol, methyl ethyl ketone, toluene, tetrahydrofuran and combinations thereof and drying.

### Claim 51 (depends on 13, 14, 15, 16, 17, 18, 19, 20)

The compound according to any one of claims 13 to 20 having crystalline solid form B obtained by crystallizing (−)-halofenate from at least one solvent selected from the group consisting of heptane, 2-propanol, and combinations thereof and at a temperature of from about 20° C. to −10° C. and drying until the crystals contain from about 2 to about 3% solvent.

### Claim 52 (depends on 21, 22, 23, 24)

The compound according to any one of claims 21 to 24 having crystalline solid form C obtained by crystallizing (−)-halofenate from at least one solvent selected from the group consisting of heptane, 2-propanol, and combinations thereof and at a temperature of from about 20° C. to −10° C. and drying until the crystals contain about 0.05% to about 0.3% solvent.

### Claim 53 (depends on 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36)

The compound according to any one of claims 25 to 36 having crystalline solid form D obtained by crystallizing (−)-halofenate from at least one solvent selected from the group consisting of acetone, ethanol, dichloromethane and combinations thereof and drying.

### Claim 54 (depends on 37, 38, 39, 40, 41, 42, 43, 44, 45, 46)

The compound according to any one of claims 37 to 46 having crystalline solid form E obtained by crystallizing (−)-halofenate from hexanes and at least one solvent selected from the group consisting of t-butyl methyl ether and 2-propanol and drying.

### Claim 55 (depends on 47, 48, 49)

The compound according to any one of claims 47 to 49 in amorphous form obtained by heating (−)-halofenate in high humidity.

### Claim 56 (depends on 55)

The compound of claim 55 in amorphous form obtained by heating (−)-halofenate at greater than about 60° C. for at least about 3 weeks in at least about 70% humidity.

### Claim 57

The compound (−)-halofenate in a form selected from the group consisting of crystalline solid form A, B, C, D, E and amorphous that is in an isolated form.

### Claim 58 (depends on 57)

A compound of claim 57 in substantially pure form A.

### Claim 59 (depends on 57)

A compound of claim 57 in substantially pure form B.

### Claim 60 (depends on 57)

A compound of claim 57 in substantially pure form C.

### Claim 61 (depends on 57)

A compound of claim 57 in substantially pure form D.

### Claim 62 (depends on 57)

A compound of claim 57 in substantially pure form E.

### Claim 63 (depends on 57)

A compound of claim 57 in substantially pure amorphous form.

### Claim 64

The compound according to any one of the preceding claims consisting of greater than 91% (−)-halofenate and less than 9% of chemical impurities other than (−)-halofenate based on the total weight of (−)-halofenate.

### Claim 65 (depends on 64)

The compound of claim 64 consisting of greater than 92% by weight of (−)-halofenate.

### Claim 66 (depends on 64)

The compound of claim 64 consisting of greater than 93% by weight of (−)-halofenate.

### Claim 67 (depends on 64)

The compound of claim 64 consisting of greater than 94% by weight of (−)-halofenate.

### Claim 68 (depends on 64)

The compound of claim 64 consisting of greater than 95% by weight of (−)-halofenate.

### Claim 69 (depends on 64)

The compound of claim 64 consisting of greater than 96% by weight of (−)-halofenate.

### Claim 70 (depends on 64)

The compound of claim 64 consisting of greater than 97% by weight of (−)-halofenate.

### Claim 71 (depends on 64)

The compound of claim 64 consisting of greater than 98% by weight of (−)-halofenate.

### Claim 72 (depends on 64)

The compound of claim 64 consisting of greater than 99% by weight of (−)-halofenate.

### Claim 73

The compound according to any one of the preceding claims wherein at least 91% is in crystalline solid form A and less than 9% is in a form selected from the group consisting of B, C, D, E and amorphous based on the total weight of (−)-halofenate.

### Claim 74 (depends on 73)

The compound of claim 73 wherein at least 92% by weight is in crystalline solid form A.

### Claim 75 (depends on 73)

The compound of claim 73 wherein at least 93% by weight is in crystalline solid form A.

### Claim 76 (depends on 73)

The compound of claim 73 wherein at least 94% by weight is in crystalline solid form A.

### Claim 77 (depends on 73)

The compound of claim 73 wherein at least 95% by weight is in crystalline solid form A.

### Claim 78 (depends on 73)

The compound of claim 73 wherein at least 96% by weight is in crystalline solid form A.

### Claim 79 (depends on 73)

The compound of claim 73 wherein at least 97% by weight is in crystalline solid form A.

### Claim 80 (depends on 73)

The compound of claim 73 wherein at least 98% by weight is in crystalline solid form A.

### Claim 81 (depends on 73)

The compound of claim 73 wherein at least 99% by weight is in crystalline solid form A.

### Claim 82

The compound according to any one of the preceding claims wherein at least 91% is the (−) isomer and less than 9% is the (+) isomer based on the total weight of halofenate.

### Claim 83 (depends on 82)

The compound of claim 82 wherein at least 92% by weight is the (−) isomer.

### Claim 84 (depends on 82)

The compound of claim 82 wherein at least 93% by weight is the (−) isomer.

### Claim 85 (depends on 82)

The compound of claim 82 wherein at least 94% by weight is the (−) isomer.

### Claim 86 (depends on 82)

The compound of claim 82 wherein at least 95% by weight is the (−) isomer.

### Claim 87 (depends on 82)

The compound of claim 82 wherein at least 96% by weight is the (−) isomer.

### Claim 88 (depends on 82)

The compound of claim 82 wherein at least 97% by weight is the (−) isomer.

### Claim 89 (depends on 82)

The compound of claim 82 wherein at least 98% by weight is the (−) isomer.

### Claim 90 (depends on 82)

The compound of claim 82 wherein at least 99% by weight is the (−) isomer.

### Claim 91

A pharmaceutical composition comprising a therapeutically effective amount of a compound according to any one of the preceding claims and a pharmaceutically acceptable vehicle or carrier.

### Claim 92 (depends on 91)

A pharmaceutical composition of claim 91, wherein the composition is a solid oral composition.

### Claim 93 (depends on 91)

A pharmaceutical composition of claim 91, wherein the composition is a tablet or capsule.

### Claim 94 (depends on 91)

A pharmaceutical composition of claim 91, wherein the composition is an aerosol or dry powder for inhalation.

### Claim 95 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90)

A pharmaceutical composition comprising a therapeutically effective amount of a compound according to any one of claims 1 to 90 and an additional therapeutic agent.

### Claim 96 (depends on 95)

A pharmaceutical composition according to claim 95, wherein the additional therapeutic agent is selected from the group consisting of a sulfonylurea or other insulin secretogogue, a thiazolidinedione or other insulin sensitizers, a fibrate, a HMG-CoA reductase inhibitor, a biguanide, a bile acid binding resin, nicotinic acid, a α-glucosidase inhibitor and insulin.

### Claim 97 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

A method of producing a compound according to any one of claims 1 to 12 having crystalline solid form A comprising at least one of:
(i) heating (−)-halofenate in at least one solvent selected from the group consisting of heptane, 2-propanol, and combinations thereof; crystallizing at a temperature of from about 50° C. to −10° C. and drying until the crystals contain less than 0.05% solvent;
(ii) drying a crystal of solid form B of (−)-halofenate;
(iii) drying a crystal of solid form C of (−)-halofenate;
(iv) heating (−)-halofenate in at least one solvent selected from the group consisting of heptane, 2-propanol, and combinations thereof; crystallizing in the presence of a crystal of a solid form of (−)-halofenate at a temperature of from about 50° C. to −10° C. and drying until the crystals contain less than 0.05% solvent; and
(v) crystallizing (−)-halofenate from at least one solvent selected from the group consisting of acetonitrile, benzene, cyclohexanol, t-butyl methyl ether, methanol, methyl ethyl ketone, toluene, tetrahydrofuran and combinations thereof and drying.

### Claim 98 (depends on 13, 14, 15, 16, 17, 18, 19, 20)

A method of producing a compound according to any one of claims 13 to 20 having crystalline solid form B which comprises crystallizing (−)-halofenate from at least one solvent selected from the group consisting of heptane, 2-propanol, and combinations thereof and at a temperature of from about 20° C. to −10° C. and drying until the crystals contain from about 2 to about 3% solvent.

### Claim 99 (depends on 21, 22, 23, 24)

The method of producing a compound according to any one of claims 21 to 24 having crystalline solid form C which comprises crystallizing (−)-halofenate from at least one solvent selected from the group consisting of heptane, 2-propanol, and combinations thereof and at a temperature of from about 20° C. to −10° C. and drying until the crystals contain about 0.05% to about 0.3% solvent.

### Claim 100 (depends on 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36)

The method of producing a compound according to any one of claims 25 to 36 having crystalline solid form D which comprises crystallizing (−)-halofenate from at least one solvent selected from the group consisting of acetone, ethanol, dichloromethane and combinations thereof and drying.

### Claim 101 (depends on 37, 38, 39, 40, 41, 42, 43, 44, 45, 46)

The method of producing a compound according to any one of claims 37 to 46 having crystalline solid form E which comprises crystallizing (−)-halofenate from t-butyl methyl ether and heptane and drying.

### Claim 102 (depends on 47, 48, 49)

The method of producing compound according to any one of claims 47 to 49 in amorphous form which comprises heating (−)-halofenate in high humidity.

### Claim 103 (depends on 102)

The method of producing compound of claim 102 in amorphous form which comprises heating (−)-halofenate at greater than about 60° C. for at least about 3 weeks in at least about 74% humidity.

### Claim 104 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90)

The method of enantiomerically enriching a compound according to any one of claims 1 to 90 comprising heating (−)-halofenate in a solvent; crystallizing at a temperature of from about 50° C. to −10° C. and drying until the crystals contain less than 0.05% solvent.

### Claim 105 (depends on 104)

The method of claim 104 wherein said method provides (−)-halofenate in a solvent having an enantiomeric excess of at least about 95%.

### Claim 106 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90)

A method for preventing or treating a condition associated with blood lipid deposition in a mammal comprising administering to a mammal a therapeutically effective amount of the compound according to any one of claims 1 to 90.

### Claim 107 (depends on 106)

The method of claim 106, wherein said mammal is a human

### Claim 108 (depends on 106)

The method of claim 106, wherein at least one of said condition is selected from the group consisting of Type 2 diabetes and hyperlipidemia.

### Claim 109 (depends on 106)

The method of claim 106, wherein the compound is administered orally, parenterally or topically

### Claim 110 (depends on 106)

The method of claim 106, wherein the compound is administered in combination with a second therapeutic agent.

### Claim 111 (depends on 110)

The method of claim 110, wherein the second therapeutic agent is selected from the group consisting of a sulfonylurea or other insulin secretogogue, a thiazolidinedione or other insulin sensitizers, a fibrate, a HMG-CoA reductase inhibitor, a biguanide, a bile acid binding resin, nicotinic acid, a α-glucosidase inhibitor and insulin.

### Claim 112 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90)

A method for the preparation of a pharmaceutical composition comprising admixing a therapeutically effective amount of according to any one of claims 1 to 90 with a pharmaceutically acceptable vehicle or carrier.

### Claim 113

A composition comprising at least one solid form of (−) halofenate wherein said solid form is selected from the group consisting of Form A, Form B, Form C, Form D, Form E, and the amorphous form.

### Claim 114

A composition comprising at least two solid forms of (−) halofenate wherein each solid form is independently selected from the group consisting of Form A, Form B, Form C, Form D, and the amorphous form.

### Claim 115

A pharmaceutical composition of (−) halofenate comprising Form A of (−) halofenate, a solid form of (−) halofenate selected from the group consisting of Form B, Form C, Form D, Form E, the amorphous form and combinations thereof; and at least one pharmaceutically acceptable excipient.

### Claim 116 (depends on 115)

The pharmaceutical composition of claim 115 wherein Form A is present in a therapeutically effective amount.

### Claim 117 (depends on 115)

The pharmaceutical composition of claim 115 wherein Form A and at least one of Form B, Form C, Form D, Form E, and the amorphous form are present in a therapeutically effective amount.

### Claim 118 (depends on 113, 114, 115, 116, 117)

The pharmaceutical composition of claims 113 to 117, wherein the composition is selected from the group consisting of a solid oral composition, a tablet, a capsule, and a dry powder for inhalation.

### Claim 119 (depends on 5, 11)

The compound (−)-halofenate in a crystalline solid Form A of claim 5 or 11 further characterized by an infrared spectrum comprising peaks at about 3322 cm−1 and about 2886 cm−1.

### Claim 120 (depends on 5, 11)

The compound (−)-halofenate in a crystalline solid Form A of claim 5 or 11 further characterized by a Raman spectrum comprising peaks at about 3087 cm−1 and about 1663 cm−1.

### Claim 121 (depends on 119)

The compound (−)-halofenate in a crystalline solid Form A of claim 119 further characterized by a Raman spectrum comprising peaks at about 3087 cm−1 and about 1663 cm'.

### Claim 122

A pharmaceutical composition comprising a therapeutically effective amount of (−) halofenate in crystalline solid Form A characterized by an X-ray powder diffraction pattern comprising peaks at about 10.8°2θ, about 22.0°2θ, about 29.3°2θ and a Raman spectrum comprising at least one peak selected from about 3087 cm−1 and about 1663 cm'; and at least one pharmaceutically acceptable excipient.

### Claim 123 (depends on 15, 19)

The compound (−)-halofenate in a crystalline solid Form B of claim 15 or 19 further characterized by at least one x-ray powder diffraction peak selected from about 18.8°2θ, about 20.1°2θ, and about 14.0°2θ.

### Claim 124

A pharmaceutical composition comprising a therapeutically effective amount of (−) halofenate in crystalline solid Form B characterized by an X-ray Powder diffraction pattern comprising peaks at about 6.2°2θ and about 12.4°2θ, and at least one peak selected from about 18.8°2θ, about 20.1θ2°, and about 14.0°2θ; and at least one pharmaceutically acceptable excipient.

### Claim 125 (depends on 22, 24)

The compound (−)-halofenate in a crystalline solid Form C of claim 22 or 24 further characterized by at least one x-ray powder diffraction peak selected from about 15.5°2θ, about 23.1°2θ, about 14.7°2θ, and about 25.9°2θ.

### Claim 126

A pharmaceutical composition comprising a therapeutically effective amount of (−) halofenate in crystalline solid Form C characterized by an X-ray Powder diffraction pattern comprising peaks at about 9.9°2θ and about 13.3°2θ, and at least one peak selected from about 15.5°2θ, about 23.1°2θ, about 14.7°2θ, and about 25.9°2θ; and at least one pharmaceutically acceptable excipient.

### Claim 127 (depends on 29, 35)

The compound (−)-halofenate in a crystalline solid Form D of claim 29 or 35 further characterized by an infrared spectrum comprising at least one peak selected from about 3469 cm−1 and about 2870 cm−1.

### Claim 128 (depends on 29, 35)

The compound (−)-halofenate in a crystalline solid Form D of claim 29 or 35 further characterized by a Raman spectrum comprising peaks at about 3077 cm−1 and about 1329 cm−1.

### Claim 129 (depends on 127)

The compound (−)-halofenate in a crystalline solid Form D of claim 127 further characterized by a Raman spectrum comprising peaks at about 3077 cm−1 and about 1329 cm−1.

### Claim 130

A pharmaceutical composition comprising a therapeutically effective amount of (−) halofenate in crystalline solid Form D characterized by an X-ray Powder diffraction pattern comprising peaks at about 9.6°2θ and about 17.4°2θ, and a Raman spectrum comprising at least one peak selected from about 3077 cm−1 and about 1329 cm−1;
and at least one pharmaceutically acceptable excipient.

### Claim 131 (depends on 41, 46)

The compound (−)-halofenate in a crystalline solid Form E of claim 41 or 46 further characterized by an infrared spectrum comprising at least one peak selected from about 3092 cm−1, about 2871 cm−1, and about 1563 cm−1.

### Claim 132 (depends on 41, 46)

The compound (−)-halofenate in a crystalline solid Form E of claim 41 or 46 further characterized by a Raman spectrum comprising at least one peak selected from about 2969 cm−1, about 1746 cm−1, and about 1657 cm−1.

### Claim 133 (depends on 132)

The compound (−)-halofenate in a crystalline solid Form E of claim 132 further characterized by a Raman spectrum comprising at least one peak selected from about 2969 cm−1, about 1746 cm−1, and about 1657 cm−1.

### Claim 134

A pharmaceutical composition comprising a therapeutically effective amount of (−) halofenate in crystalline solid Form E characterized by an X-ray Powder diffraction pattern comprising peaks at about 11.8°2θ and about 13.0°2θ and a Raman spectrum comprising at least one peak selected from about 2969 cm−1, about 1746 cm−1, and about 1657 cm−1; and at least one pharmaceutically acceptable excipient.

### Claim 135

A pharmaceutical composition comprising a therapeutically effective amount of (−) halofenate in an amorphous form characterized by a broad peak between about 15°2θ and about 30°2θ; and at least one pharmaceutically acceptable carrier excipient.

### Claim 136 (depends on 118)

The pharmaceutical composition of claim 118 wherein the solid oral composition is a tablet or a capsule.

### Claim 137

The compound of (−) halofenate in a crystalline solid Form A characterized by an X-ray Powder diffraction pattern comprising a peak at about 10.8°2θ and an infrared spectrum comprising at least one peak selected from about 3322 cm−1 and about 2886 cm−1.

### Claim 138

The compound of (−) halofenate in a crystalline solid Form A characterized by an X-ray Powder diffraction pattern comprising a peak at about 10.8°2θ and a Raman spectrum comprising at least one peak selected from about 3087 cm−1 and about 1663 cm−1.

### Claim 139 (depends on 137)

The compound of claim 137 further characterized by a Raman spectrum comprising at least one peak selected from about 3087 cm−1 and about 1663 cm−1.
